JP2014510755A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510755A5
JP2014510755A5 JP2014502770A JP2014502770A JP2014510755A5 JP 2014510755 A5 JP2014510755 A5 JP 2014510755A5 JP 2014502770 A JP2014502770 A JP 2014502770A JP 2014502770 A JP2014502770 A JP 2014502770A JP 2014510755 A5 JP2014510755 A5 JP 2014510755A5
Authority
JP
Japan
Prior art keywords
azacytidine
salt
protected
acid
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014502770A
Other languages
English (en)
Japanese (ja)
Other versions
JP6289361B2 (ja
JP2014510755A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/031059 external-priority patent/WO2012135405A1/en
Publication of JP2014510755A publication Critical patent/JP2014510755A/ja
Publication of JP2014510755A5 publication Critical patent/JP2014510755A5/ja
Application granted granted Critical
Publication of JP6289361B2 publication Critical patent/JP6289361B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014502770A 2011-03-31 2012-03-29 5−アザシチジンの合成 Active JP6289361B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161470392P 2011-03-31 2011-03-31
US61/470,392 2011-03-31
PCT/US2012/031059 WO2012135405A1 (en) 2011-03-31 2012-03-29 Systhesis of 5-azacytidine

Publications (3)

Publication Number Publication Date
JP2014510755A JP2014510755A (ja) 2014-05-01
JP2014510755A5 true JP2014510755A5 (enExample) 2015-05-07
JP6289361B2 JP6289361B2 (ja) 2018-03-07

Family

ID=46000343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014502770A Active JP6289361B2 (ja) 2011-03-31 2012-03-29 5−アザシチジンの合成

Country Status (13)

Country Link
US (1) US9951098B2 (enExample)
EP (1) EP2691408B1 (enExample)
JP (1) JP6289361B2 (enExample)
KR (1) KR20140019820A (enExample)
CN (1) CN103619864A (enExample)
AU (1) AU2012236476A1 (enExample)
BR (1) BR112013025167A2 (enExample)
IL (1) IL228604A0 (enExample)
MX (1) MX2013010945A (enExample)
RU (1) RU2013148580A (enExample)
SG (1) SG193622A1 (enExample)
WO (1) WO2012135405A1 (enExample)
ZA (1) ZA201307142B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2695609T (pt) 2008-05-15 2020-03-02 Celgene Corp Formulações orais de análogos da citidina e métodos de utilização dos mesmos
CA2825152A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
WO2014160698A1 (en) * 2013-03-26 2014-10-02 Celgene Corporation SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US10221216B2 (en) 2013-04-11 2019-03-05 Carnegie Mellon University Template-directed γPNA synthesis process and γPNA targeting compounds
WO2014169206A2 (en) 2013-04-11 2014-10-16 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
CN103450303A (zh) * 2013-09-04 2013-12-18 重庆泰濠制药有限公司 阿扎胞苷晶型a、阿扎胞苷晶型b及其制备方法
CN104672289A (zh) * 2013-11-29 2015-06-03 南京圣和药业股份有限公司 一种阿扎胞苷杂质的制备方法
WO2017183215A1 (ja) * 2016-04-21 2017-10-26 大原薬品工業株式会社 5-アザシチジン類の糖部シリルエーテル誘導体
CN109923105A (zh) 2016-09-26 2019-06-21 卡耐基梅隆大学 二价核碱基化合物及其用途
CN109305992A (zh) * 2017-07-28 2019-02-05 江苏先声药业有限公司 一种阿扎胞苷的制备方法
CN109988207B (zh) * 2017-12-29 2022-01-04 江苏豪森药业集团有限公司 阿扎胞苷晶型的制备方法
CN110092807A (zh) * 2018-01-30 2019-08-06 中国医学科学院药物研究所 一种高纯、低灼烧残渣的制备阿扎胞苷的方法
CA3211506A1 (en) 2018-02-07 2019-08-15 Lovelace Biomedical Research Institute Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer
KR20190136284A (ko) * 2018-05-30 2019-12-10 주식회사 삼양바이오팜 안정한 아자시티딘-함유 약제학적 조성물의 제조방법
WO2022113069A1 (en) 2020-11-24 2022-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
KR20230035524A (ko) 2020-05-01 2023-03-14 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. Covid-19 치료제로서 e 단백질 채널 차단제 및 orf3 억제제
CN113201039B (zh) * 2021-05-19 2022-04-29 南京德克瑞医药化工有限公司 一种医药中间体2’,3’,5’-三乙酰阿扎胞苷的制备方法
US20250195653A1 (en) 2023-11-28 2025-06-19 Sanofi Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (enExample) 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
CZ120699A3 (cs) * 1996-10-16 1999-09-15 Icn Pharmaceuticals, Inc. Monocyklická L-nukleosidová analoga a jejich využití
EP1545558A4 (en) 2002-09-24 2010-02-17 Koronis Pharmaceuticals Inc 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
CN101856348A (zh) 2003-08-29 2010-10-13 斯隆-凯特林癌症研究所 联合治疗癌症的方法
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
EP2118117A2 (en) 2007-01-11 2009-11-18 IVAX Pharmaceuticals s.r.o. Solid state forms of 5-azacytidine and processes for preparation thereof
US20110288042A1 (en) 2007-08-02 2011-11-24 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JP2011505336A (ja) 2007-11-01 2011-02-24 セルジーン コーポレイション 骨髄異形成症候群治療のためのシチジンアナログ
PT2695609T (pt) 2008-05-15 2020-03-02 Celgene Corp Formulações orais de análogos da citidina e métodos de utilização dos mesmos
WO2010014883A2 (en) 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
ES2400779T3 (es) 2008-08-06 2013-04-12 Sicor, Inc. Proceso para preparar un producto intermedio de azacitidina
KR101660549B1 (ko) * 2008-08-08 2016-09-27 시노팜 타이완 리미티드 5―아자시토신 뉴클레오시드 및 이의 유도체의 제조 방법
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
IT1399195B1 (it) 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina

Similar Documents

Publication Publication Date Title
JP2014510755A5 (enExample)
RU2013148580A (ru) Синтез 5-азацитидина
CN106061972B (zh) 5-氟-4-亚氨基-3-(烷基/取代烷基)-1-(芳基磺酰基)-3,4-二氢嘧啶-2(1h)-酮及其制备方法
TWI657088B (zh) 製造稠合雜環化合物之方法
TWI663160B (zh) 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TWI658042B (zh) 雜環化合物的合成
JP2015530367A5 (enExample)
JP2014521726A5 (enExample)
JP2013505259A5 (enExample)
JP2010503694A5 (enExample)
JP2010505926A5 (enExample)
JP2013535220A5 (enExample)
JP2014501790A5 (enExample)
RU2014110400A (ru) Способ и промежуточные соединения для получения макролактамов
JP2010540426A5 (enExample)
JP2018502909A5 (enExample)
JP2013518092A5 (enExample)
RU2014126224A (ru) Способ получения и очистки солей акриламидо-2-метилпропансульфоновой кислоты
US9624258B2 (en) Polymorph of regadenoson
JP7144873B2 (ja) スガマデクスナトリウム塩の製造方法
JP5315335B2 (ja) トポテカンの製造方法
JP2014520796A5 (enExample)
HRP20120550T1 (hr) Postupak pripreme derivata benzoilbenzenacetamida
CN108623602A (zh) 一种制备和纯化依鲁替尼的方法
JP2017514846A5 (enExample)